PNC Financial Services Group
CAPR icon

PNC Financial Services Group’s Capricor Therapeutics CAPR Stock Holding History

PNC Financial Services Group’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$730 Buy
24
+3
+14% +$80 ﹤0.01% 4825
2025
Q4 		$606 Sell
21
-217
-91% -$2.83K ﹤0.01% 4799
2025
Q3 		$1.72K Buy
+238
New +$1.75K ﹤0.01% 4544

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PNC Financial Services Group's CAPR Position: Q1 2026 in Review

PNC Financial Services Group increased its Capricor Therapeutics (CAPR) stake by 14% in Q1 2026, buying an estimated $80 and bringing the position to 24 shares worth $730. The position accounts for ﹤0.01% of the portfolio, ranked #4825.

PNC Financial Services Group first reported a position in CAPR in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.72K in Q3 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • PNC Financial Services Group held 24 shares of Capricor Therapeutics worth $730 as of Q1 2026.
  • PNC Financial Services Group bought 3 Capricor Therapeutics shares in Q1 2026, an estimated $80.
  • Capricor Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4825 holding.
  • PNC Financial Services Group first reported a position in Capricor Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • PNC Financial Services Group's Capricor Therapeutics position peaked at $1.72K in Q3 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.